Search research articles
Contact Us
Filters
Showing results (651-660 of 670) with videos related to
Page
of 67
Sort By:
Targeted Oncology
|
December 16, 2016
Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer
Jean-Luc Van Laethem, Hanno Riess, Jacek Jassem, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 22, 2022
Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study
John Bridgewater, Peter Fletcher, Daniel H Palmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 20, 2021
Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial
Mary F Mulcahy, Armeen Mahvash, Marc Pracht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 29, 2018
Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with <i>RAS</i>-Mutated Hepatocellular Carcinoma
Ho Yeong Lim, Philippe Merle, Karl Heinz Weiss, et al.
Nature
|
July 17, 2012
Gut microbiota composition correlates with diet and health in the elderly
Marcus J Claesson, Ian B Jeffery, Susana Conde, et al.
Journal of Hepatology
|
April 18, 2016
Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma
Ghassan K Abou-Alfa, Oscar Puig, Bruno Daniele, et al.
The Lancet. Oncology
|
March 30, 2019
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
John N Primrose, Richard P Fox, Daniel H Palmer, et al.
Liver Cancer
|
March 6, 2023
Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial
Zhenggang Ren, Michel Ducreux, Ghassan K Abou-Alfa, et al.
The Lancet. Oncology
|
June 24, 2014
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
Gary Middleton, Paul Silcocks, Trevor Cox, et al.
Cancers
|
June 2, 2021
COVID-19 Risk Factors for Cancer Patients: A First Report with Comparator Data from COVID-19 Negative Cancer Patients
Beth Russell, Charlotte L Moss, Kieran Palmer, et al.
Page
of 67
Search research articles
Search
Showing results (651-660 of 670) with videos related to
Sort By:
Page
of 67
Targeted Oncology
|
December 16, 2016
Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer
Jean-Luc Van Laethem, Hanno Riess, Jacek Jassem, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 22, 2022
Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study
John Bridgewater, Peter Fletcher, Daniel H Palmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 20, 2021
Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial
Mary F Mulcahy, Armeen Mahvash, Marc Pracht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 29, 2018
Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with <i>RAS</i>-Mutated Hepatocellular Carcinoma
Ho Yeong Lim, Philippe Merle, Karl Heinz Weiss, et al.
Nature
|
July 17, 2012
Gut microbiota composition correlates with diet and health in the elderly
Marcus J Claesson, Ian B Jeffery, Susana Conde, et al.
Journal of Hepatology
|
April 18, 2016
Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma
Ghassan K Abou-Alfa, Oscar Puig, Bruno Daniele, et al.
The Lancet. Oncology
|
March 30, 2019
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
John N Primrose, Richard P Fox, Daniel H Palmer, et al.
Liver Cancer
|
March 6, 2023
Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial
Zhenggang Ren, Michel Ducreux, Ghassan K Abou-Alfa, et al.
The Lancet. Oncology
|
June 24, 2014
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
Gary Middleton, Paul Silcocks, Trevor Cox, et al.
Cancers
|
June 2, 2021
COVID-19 Risk Factors for Cancer Patients: A First Report with Comparator Data from COVID-19 Negative Cancer Patients
Beth Russell, Charlotte L Moss, Kieran Palmer, et al.
Page
of 67